Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 16/20 | 0.69 |
| ▸ | MMP3 | P08254 | 11/20 | 0.69 |
| ▸ | MMP1 | P03956 | 6/20 | 0.50 |
| ▸ | MMP9 | P14780 | 4/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758581 | 0.84 | MMP3 (0.61) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL7406850 | 0.83 | MMP2 (0.50) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL4633112 | 0.80 | MMP3 (0.74) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL5088865 | 0.80 | MMP3 (0.74) | MMP2MMP3MMP1MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL7765095 | 0.80 | MMP2 (0.52) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL8773896 | 0.77 | MME (0.60) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL8777512 | 0.76 | MMP3 (0.59) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL8777504 | 0.75 | MMP2 (0.57) | MMP2MMP3MMP1MMP9MMP8 | |
| SCHEMBL7604668 | 0.75 | MMP2 (0.55) | MMP2MMP3 | |
| SCHEMBL7604680 | 0.75 | MMP2 (0.55) | MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |